Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton Sells 2,980 Shares

Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 2,980 shares of the company’s stock in a transaction on Monday, March 24th. The stock was sold at an average price of $6.94, for a total transaction of $20,681.20. Following the transaction, the chief executive officer now directly owns 762,419 shares in the company, valued at approximately $5,291,187.86. This trade represents a 0.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jerrell Shelton also recently made the following trade(s):

• On Monday, March 17th, Jerrell Shelton sold 4,620 shares of Cryoport stock. The stock was sold at an average price of $6.29, for a total transaction of $29,059.80.
• On Monday, March 10th, Jerrell Shelton sold 4,173 shares of Cryoport stock. The shares were sold at an average price of $4.88, for a total transaction of $20,364.24.

Cryoport Stock Performance

Cryoport stock opened at $6.24 on Friday. The stock has a fifty day moving average of $6.71 and a two-hundred day moving average of $7.33. Cryoport, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $20.11. The company has a market capitalization of $311.44 million, a price-to-earnings ratio of -1.85 and a beta of 1.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The business had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. During the same quarter last year, the firm posted ($0.29) earnings per share. On average, analysts anticipate that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. UBS Group upgraded Cryoport from a “neutral” rating to a “buy” rating and set a $10.00 price target on the stock in a report on Monday. Guggenheim assumed coverage on Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Cryoport in a research note on Wednesday, March 5th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $11.67.

Institutional Investors Weigh In On Cryoport

A number of institutional investors have recently bought and sold shares of CYRX. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Cryoport by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after purchasing an additional 2,120 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Cryoport in the fourth quarter valued at $51,000. Avanza Fonder AB purchased a new stake in Cryoport during the fourth quarter valued at about $64,000. Quarry LP acquired a new stake in Cryoport during the fourth quarter worth about $69,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Cryoport in the 3rd quarter worth about $82,000. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.